Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
C The Molecular docking results of four biomarkers with key drugsInteraction scores of T2D with biomarkersGene SymbolGene IDDisease NameDisease IDDirect EvidenceInference NetworkInference ScoreReference CountCDKN1A1026Diabetes Mellitus, Type 2MESH:D003924Air Pollutants|alpha-Tocopherol|Arsenic|Ascorbic Acid|Berberine|bis(4-hydroxyphenyl)sulfone|bisphenol A|Cadmium|Chromium|cinnamaldehyde|Copper|coumarin|Curcumin|daidzein|Dibutyl Phthalate|Dietary Fats|Diethylnitrosamine|Drugs, Chinese Herbal|epigallocatechin gallate|Folic Acid|Genistein|ginsenoside Re|Gliclazide|Glucose|Glutathione|Hemin|Irbesartan|Iron|Lead|Manganese|Metformin|Niacinamide|Nickel|Nicotine|Orlistat|Particulate Matter|perfluorooctane sulfonic acid|perfluorooctanoic acid|perfluoroundecanoic acid|Pesticides|Pioglitazone|Plant Extracts|Polychlorinated Biphenyls|Resveratrol|Rosiglitazone|Silver|Streptozocin|TAK-875|titanium dioxide|Tolbutamide|Troglitazone|Vehicle Emissions|Zinc77.81151MIOX55,586Diabetes Mellitus, Type 2MESH:D003924bisphenol A|Dibutyl Phthalate|Diethylnitrosamine|Folic Acid|Iron|perfluorooctanoic acid|Plant Extracts|Resveratrol|Rosiglitazone|titanium dioxide|Troglitazone|Vehicle Emissions34.3455MYCN4613Diabetes Mellitus, Type 2MESH:D003924Air Pollutants|bisphenol A|Copper|coumarin|Dietary Fats|Diethylnitrosamine|Folic Acid|Genistein|Pantothenic Acid|perfluoroundecanoic acid|Resveratrol|Silver|titanium dioxide28.4638CD823732Diabetes Mellitus, Type 2MESH:D003924Ascorbic Acid|bis(4-hydroxyphenyl)sulfone|bisphenol A|Dibutyl Phthalate|Dietary Fats|Genistein|Glucose|Lead|Particulate Matter|perfluorooctane sulfonic acid|perfluorooctanoic acid|Vehicle Emissions29.4733Interaction scores and networks between Type 2 diabetes mellitus (T2DM) and biomarkersChemical NameChemical IDCAS RNGene SymbolGene IDInteractionInteraction ActionsReference CountOrganism Countbisphenol AC006780########CD823732bisphenol A results in decreased expression of CD82 mRNAdecreases^expression42ArsenicD0011517440: 38-2CDKN1A1026Arsenic results in increased expression of CDKN1A mRNAincreases^expression21CadmiumD0021047440: 43-9CDKN1A1026[Cadmium Chloride results in increased abundance of Cadmium] which results in increased expression of CDKN1A mRNAincreases^expression21Dibutyl PhthalateD00399384: 74-2CDKN1A1026Dibutyl Phthalate results in increased expression of CDKN1A mRNAincreases^expression22Drugs, Chinese HerbalD004365CDKN1A1026Drugs, Chinese Herbal results in increased expression of CDKN1A mRNAincreases^expression21SilverD0128347440: 22-4CDKN1A1026Silver analog results in increased expression of CDKN1A mRNAincreases^expression21titanium dioxideC00949513,463 to 67-7CDKN1A1026titanium dioxide results in decreased expression of CDKN1A mRNAdecreases^expression22Dibutyl PhthalateD00399384: 74-2MIOX55,586Dibutyl Phthalate results in decreased expression of MIOX mRNAdecreases^expression21perfluorooctanoic acidC023036335: 67-1MIOX55,586perfluorooctanoic acid results in increased expression of MIOX mRNAincreases^expression22alpha-TocopherolD024502########CDKN1A1026alpha-Tocopherol inhibits the reaction [Acrylonitrile results in increased expression of CDKN1A mRNA]increases^expression11Ascorbic AcidD00120550: 81-7CDKN1A1026[Ascorbic Acid co-treated with Zinc Acetate co-treated with motexafin gadolinium] results in decreased expression of CDKN1A mRNAdecreases^expression11bis(4-hydroxyphenyl)sulfoneC543008########CDKN1A1026bis(4-hydroxyphenyl)sulfone results in decreased expression of CDKN1A mRNAdecreases^expression11bisphenol AC006780########CDKN1A1026[bisphenol A co-treated with cylindrospermopsin] results in increased expression of CDKN1A mRNAincreases^expression11ChromiumD0028577440: 47-3CDKN1A1026Chromium results in decreased expression of CDKN1A mRNAdecreases^expression11cinnamaldehydeC012843CDKN1A1026cinnamaldehyde results in increased expression of CDKN1A mRNAincreases^expression11CopperD0033007440: 50-8CDKN1A1026[Chelating Agents binds to Copper] which results in increased expression of CDKN1A mRNAincreases^expression11coumarinC03012391: 64-5CDKN1A1026coumarin analog results in increased expression of CDKN1A mRNAincreases^expression11CurcuminD003474458: 37-7CDKN1A1026[Curcumin binds to and results in increased activity of VDR protein] which results in increased expression of CDKN1A mRNAincreases^expression11Dietary FatsD004041CDKN1A1026[Dietary Fats co-treated with Choline deficiency] results in increased expression of CDKN1A mRNAincreases^expression11DiethylnitrosamineD00405255: 18-5CDKN1A1026AHR protein inhibits the reaction [Diethylnitrosamine results in decreased expression of CDKN1A mRNA]decreases^expression11epigallocatechin gallateC045651989: 51-5CDKN1A1026[epigallocatechin gallate co-treated with leptomycin B] results in increased expression of CDKN1A mRNAincreases^expression11Folic AcidD00549259: 30-3CDKN1A1026[1,2-Dimethylhydrazine co-treated with Folic Acid] results in decreased expression of CDKN1A mRNAdecreases^expression11GenisteinD019833446: 72-0CDKN1A1026[Calcitriol co-treated with Genistein] results in increased expression of CDKN1A mRNAincreases^expression11ginsenoside ReC04986452,286 to 59-6CDKN1A1026ginsenoside Re results in increased expression of CDKN1A mRNAincreases^expression11GliclazideD00590721,187 to 98-4CDKN1A1026Gliclazide inhibits the reaction [Hydrogen Peroxide results in increased expression of CDKN1A mRNA]increases^expression11GlucoseD00594750: 99-7CDKN1A1026[Glucose co-treated with Deferoxamine] results in increased expression of CDKN1A mRNAincreases^expression11IronD0075017439: 89-6CDKN1A1026[Nickel co-treated with Iron co-treated with Tungsten] results in increased expression of CDKN1A mRNAincreases^expression11ManganeseD0083457439: 96-5CDKN1A1026Manganese deficiency results in increased expression of CDKN1A mRNAincreases^expression11MetforminD008687657: 24-9CDKN1A1026Metformin inhibits the reaction [Testosterone results in decreased expression of CDKN1A mRNA]decreases^expression11NiacinamideD00953698: 92-0CDKN1A1026[Butyric Acid co-treated with Niacinamide co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in decreased expression of CDKN1A mRNA]decreases^expression11NickelD0095327440: 02-0CDKN1A1026[Nickel co-treated with Cobalt co-treated with Tungsten] results in increased expression of CDKN1A mRNAincreases^expression11NicotineD009538CDKN1A1026Acetylcysteine inhibits the reaction [Nicotine results in increased expression of CDKN1A mRNA]increases^expression11Particulate MatterD052638CDKN1A10264-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Particulate Matter results in increased expression of CDKN1A mRNA]increases^expression11perfluorooctane sulfonic acidC0769941763: 23-1CDKN1A1026perfluorooctane sulfonic acid results in decreased expression of CDKN1A mRNAdecreases^expression11perfluorooctanoic acidC023036335: 67-1CDKN1A1026perfluorooctanoic acid inhibits the reaction [Calcitriol results in increased expression of CDKN1A mRNA]increases^expression11perfluoroundecanoic acidC586085CDKN1A1026perfluoroundecanoic acid results in increased expression of CDKN1A mRNAincreases^expression11PesticidesD010575CDKN1A1026Pesticides results in decreased expression of CDKN1A mRNAdecreases^expression11Plant ExtractsD010936CDKN1A1026[Plant Extracts co-treated with Glucaric Acid] inhibits the reaction [9,10-Dimethyl-1,2-benzanthracene results in increased expression of CDKN1A mRNA]increases^expression11Polychlorinated BiphenylsD011078CDKN1A1026Polychlorinated Biphenyls analog results in decreased expression of CDKN1A mRNAdecreases^expression11ResveratrolD000077185CDKN1A10262-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Resveratrol results in increased expression of CDKN1A mRNA]increases^expression11RosiglitazoneD000077154CDKN1A1026Rosiglitazone results in decreased expression of CDKN1A mRNAdecreases^expression11StreptozocinD01331118,883 to 66-4CDKN1A10262-amino-6-boronohexanoic acid inhibits the reaction [Streptozocin results in increased expression of CDKN1A mRNA]increases^expression11TAK-875C557331CDKN1A1026TAK-875 results in increased expression of CDKN1A mRNAincreases^expression11TroglitazoneD00007728897,322 to 87-7CDKN1A1026[Troglitazone co-treated with IFNG protein] results in increased expression of CDKN1A mRNAincreases^expression11Vehicle EmissionsD001335CDKN1A10264-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline inhibits the reaction [Vehicle Emissions results in increased expression of CDKN1A mRNA]increases^expression11ZincD0150327440: 66-6CDKN1A1026[PCI 5002 co-treated with Zinc] results in increased expression of CDKN1A mRNAincreases^expression11bisphenol AC006780########MIOX55,586bisphenol A results in decreased expression of MIOX mRNAdecreases^expression11DiethylnitrosamineD00405255: 18-5MIOX55,586Diethylnitrosamine results in increased expression of MIOX mRNAincreases^expression11Folic AcidD00549259: 30-3MIOX55,586[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in increased expression of MIOX mRNAincreases^expression11Plant ExtractsD010936MIOX55,586[Plant Extracts co-treated with Resveratrol] results in decreased expression of MIOX mRNAdecreases^expression11ResveratrolD000077185MIOX55,586[Plant Extracts co-treated with Resveratrol] results in decreased expression of MIOX mRNAdecreases^expression11RosiglitazoneD000077154MIOX55,586Rosiglitazone results in increased expression of MIOX mRNAincreases^expression11titanium dioxideC00949513,463 to 67-7MIOX55,586[titanium dioxide co-treated with Azoxymethane co-treated with Dextran Sulfate] results in decreased expression of MIOX mRNAdecreases^expression11TroglitazoneD00007728897,322 to 87-7MIOX55,586Troglitazone results in increased expression of MIOX mRNAincreases^expression11Air PollutantsD000393MYCN4613[Air Pollutants results in increased abundance of [Ozone co-treated with Soot]] which results in increased expression of MYCN mRNAincreases^expression11bisphenol AC006780########MYCN4613bisphenol A results in increased expression of MYCN mRNAincreases^expression11CopperD0033007440: 50-8MYCN4613[Copper co-treated with Chlorpyrifos] results in increased expression of MYCN mRNAincreases^expression11Dietary FatsD004041MYCN4613Dietary Fats results in increased expression of MYCN mRNAincreases^expression11DiethylnitrosamineD00405255: 18-5MYCN4613[Diethylnitrosamine co-treated with Phenobarbital] results in increased expression of MYCN mRNAincreases^expression11Folic AcidD00549259: 30-3MYCN4613[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased expression of MYCN mRNAdecreases^expression11GenisteinD019833446: 72-0MYCN4613Genistein results in increased expression of MYCN mRNAincreases^expression11Pantothenic AcidD01020579: 83-4MYCN4613Pantothenic Acid results in increased expression of MYCN mRNAincreases^expression11perfluoroundecanoic acidC586085MYCN4613perfluoroundecanoic acid results in increased expression of MYCN mRNAincreases^expression11ResveratrolD000077185MYCN4613Resveratrol inhibits the reaction [Dietary Fats results in increased expression of MYCN mRNA]increases^expression11SilverD0128347440: 22-4MYCN4613Silver results in decreased expression of MYCN mRNAdecreases^expression11titanium dioxideC00949513,463 to 67-7MYCN4613titanium dioxide results in decreased expression of MYCN mRNAdecreases^expression11Ascorbic AcidD00120550: 81-7CD823732Ascorbic Acid results in increased expression of CD82 mRNAincreases^expression11bis(4-hydroxyphenyl)sulfoneC543008########CD823732bis(4-hydroxyphenyl)sulfone results in increased expression of CD82 mRNAincreases^expression11Dibutyl PhthalateD00399384: 74-2CD823732Dibutyl Phthalate results in increased expression of CD82 mRNAincreases^expression11Dietary FatsD004041CD823732Dietary Fats results in decreased expression of CD82 mRNAdecreases^expression11GenisteinD019833446: 72-0CD823732Genistein results in increased expression of CD82 mRNAincreases^expression11GlucoseD00594750: 99-7CD823732[INS protein co-treated with Glucose] results in increased expression of CD82 mRNAincreases^expression10LeadD0078547439: 92-1CD823732Lead results in decreased expression of CD82 mRNAdecreases^expression11Particulate MatterD052638CD823732Particulate Matter results in decreased expression of CD82 mRNAdecreases^expression11perfluorooctane sulfonic acidC0769941763: 23-1CD823732perfluorooctane sulfonic acid results in decreased expression of CD82 mRNAdecreases^expression11perfluorooctanoic acidC023036335: 67-1CD823732perfluorooctanoic acid results in decreased expression of CD82 mRNAdecreases^expression11Vehicle EmissionsD001335CD823732[Allergens co-treated with Vehicle Emissions] results in increased expression of CD82 mRNAincreases^expression11
Source: Drug prediction. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Study design awaiting verification.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.
Meta-analysis unclear · Blinding unclear / not reported · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Identification of biomarkers and mechanism exploration of ferroptosis related genes regulated by m6A in type 2 diabetes mellitus
Study design awaiting verification · Hereditas · 2025
Original publication title
Identification of biomarkers and mechanism exploration of ferroptosis related genes regulated by m6A in type 2 diabetes mellitus
© The Author(s) 2025
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What objectives does the paper state?
This study is aims to explore the role of ferroptosis genes regulated by N6-methyladenosine (m6A) in Type 2 diabetes mellitus (T2DM).
Source: PurposeAbstract: What methods does the paper describe?
Firstly, differentially expressed m6A-FRGs (DEm6A-FRGs) were obtained by intersecting the differentially expressed genes (DEGs) and the m6A-related ferroptosis genes (m6A-FRGs). After enrichment analysis of DEm6A-FRGs, artificial neural network (ANN) and nomogram models were constructed using 4 biomarkers. Moreover, the gene set enrichment analysis of biomarkers was performed. Furthermore, the transcription factors (TF)-mRNA and competing endogenous RNAs (ceRNA) regulatory networks were constructed to reveal the potential regulation of biomarkers at molecular level. In addition, the targeted drugs of biomarkers were predicted, and the molecular docking was used to study the inter-molecular interactions between biomarkers and targeted drugs by “AutoDockvina”.
Source: Material and methodsAbstract: Results
Totals of 10 DEm6A-FRGs were obtained by intersecting the 402 DEGs and 299 m6A-FRGs. Moreover, the ANN model and nomogram model were constructed with 4 biomarkers including CDKN1A, MIOX, MYCN and CD82, among them, CDKN1A was the most important biomarker for forecasting T2DM. Notably, the function of extracellular matrix structural constituent was low expression in CD82 and MIOX, the function of mitochondrial protein-containing complex was high expression in CD82 and CDKN1A. Furthermore, TP63 could regulate CD82, CDKN1A and MIOX, GATA3 could regulate CD82, CDKN1A and MYCN at the same time.
The ceRNA network was constructed with 4 mRNAs, 51 miRNAs and 37 lncRNAs, among them, XIST was a key lncRNA that associated with 12 miRNAs, which could influence CDKN1A. In addition, bisphenol A was associated with CD82 and MYCN, CGP 25608 was associated with CDKN1A and MIOX.
Source: ResultsAbstract: Conclusion
This study revealed the potential molecular mechanisms of m6A-related ferroptosis genes in T2DM, which could provide novel insights for the clinical diagnosis and treatment of T2DM.
Source: ConclusionAuthors’ abstract
Purpose
This study is aims to explore the role of ferroptosis genes regulated by N6-methyladenosine (m6A) in Type 2 diabetes mellitus (T2DM).
Material and methods
Firstly, differentially expressed m6A-FRGs (DEm6A-FRGs) were obtained by intersecting the differentially expressed genes (DEGs) and the m6A-related ferroptosis genes (m6A-FRGs). After enrichment analysis of DEm6A-FRGs, artificial neural network (ANN) and nomogram models were constructed using 4 biomarkers. Moreover, the gene set enrichment analysis of biomarkers was performed. Furthermore, the transcription factors (TF)-mRNA and competing endogenous RNAs (ceRNA) regulatory networks were constructed to reveal the potential regulation of biomarkers at molecular level. In addition, the targeted drugs of biomarkers were predicted, and the molecular docking was used to study the inter-molecular interactions between biomarkers and targeted drugs by “AutoDockvina”.
Results
Totals of 10 DEm6A-FRGs were obtained by intersecting the 402 DEGs and 299 m6A-FRGs. Moreover, the ANN model and nomogram model were constructed with 4 biomarkers including CDKN1A, MIOX, MYCN and CD82, among them, CDKN1A was the most important biomarker for forecasting T2DM. Notably, the function of extracellular matrix structural constituent was low expression in CD82 and MIOX, the function of mitochondrial protein-containing complex was high expression in CD82 and CDKN1A. Furthermore, TP63 could regulate CD82, CDKN1A and MIOX, GATA3 could regulate CD82, CDKN1A and MYCN at the same time.
The ceRNA network was constructed with 4 mRNAs, 51 miRNAs and 37 lncRNAs, among them, XIST was a key lncRNA that associated with 12 miRNAs, which could influence CDKN1A. In addition, bisphenol A was associated with CD82 and MYCN, CGP 25608 was associated with CDKN1A and MIOX.
Conclusion
This study revealed the potential molecular mechanisms of m6A-related ferroptosis genes in T2DM, which could provide novel insights for the clinical diagnosis and treatment of T2DM.
Supplementary Information
The online version contains supplementary material available at 10.1186/s41065-025-00385-9.
Publication and source details
Original title: Identification of biomarkers and mechanism exploration of ferroptosis related genes regulated by m6A in type 2 diabetes mellitus
Jing Wang; Xuying Li; Juan Geng; Ruiduo Wang; Gang Ma; Pan Liu
Hereditas · 2025
© The Author(s) 20252025https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.Jing WangNatural Science Basic Research Program of Shanxi (Program No. 2022JQ-819)Natural Science Basic Research Program of Shanxi (Program No. 2022JQ-819)Natural Science Basic Research Program of Shanxi (Program No. 2022JQ-819)Natural Science Basic Research Program of Shanxi (Program No. 2022JQ-819)Natural Science Basic Research Program of Shanxi (Program No. 2022JQ-819)Natural Science Basic Research Program of Shanxi (Program No. 2022JQ-819)Gang MaNatural Science Foundation of Ningxia Province (Program No. 2022A1251).Natural Science Foundation of Ningxia Province (Program No. 2022A1251).Natural Science Foundation of Ningxia Province (Program No. 2022A1251).Natural Science Foundation of Ningxia Province (Program No. 2022A1251).Natural Science Foundation of Ningxia Province (Program No. 2022A1251).Natural Science Foundation of Ningxia Province (Program No. 2022A1251).Repository JATS snapshot; version as supplied
Source retrieved: 2026-11-11T06:41:59.017072+00:00
DOI: 10.1186/s41065-025-00385-9 · PMC11834627